Markus Juza

Dr. Markus Juza


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
DRDaniela Rossi
Daniela Rossi
AMAnnamaria Marra
Annamaria Marra
MRMarta Rui
Marta Rui
SBStefania Brambilla
Stefania Brambilla
MJMarkus Juza
Markus Juza
Simona CollinaSimona Collina
Simona Collina

10 September 2016 in Molecules
Verified
Journal Article
Open access
PDF file
MRMarta Rui
Marta Rui
AMAnnamaria Marra
Annamaria Marra
VPVittorio Pace
Vittorio Pace
MJMarkus Juza
Markus Juza
Daniela RossiDaniela Rossi
Daniela Rossi
Simona CollinaSimona Collina
Simona Collina
The identification of novel pan-sigma receptor (SR) modulators, potentially useful in cancer treatment, represents a new goal of our research. Here, we report on the preparation of novel chiral compounds characterized by a 3-C alkyl chain bridging an aromatic portion to a 4-benzyl-piperidine moiety. All of the studied compounds have been prepared both in racemic and enantiomerically-pure form, with the final aim to address the role of chirality in the SR interaction. To isolate and characterize enantiomeric compounds, high-performance liquid chromatography (HPLC) procedures were set up. A systematic analytical screening, involving several combinations of chiral stationary and mobile phases, allowed us to optimize the analytical resolution and to set up the (semi-)preparative chromatographic conditions. Applying the optimized procedure, the enantiomeric resolution of the studied compounds was successfully achieved, obtaining all of the compounds with an enantiomeric excess higher than 95%. Lastly, the absolute configuration has been empirically assigned to enantiopure compounds, combining the electronic circular dichroism (ECD) technique to the elution order study.